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doi:10.1016/j.ejvs.2009.02.014Abstract Objectives: To assess the possible association between inherited thrombophilic
alterations and the severity of peripheral arterial disease (PAD).
Design: A case-control study.
Methods: We evaluated the presence of G20210A prothrombin (FII) and R506Q FV Leiden muta-
tions, antithrombin, protein C and S deficiencies in 176 patients with PAD at Fontaine’s stage II
and in 106 patients with critical limb ischaemia (Fontaine’s stage III/IV) consecutively referred
to our unit. As control group, we studied 209 apparently healthy subjects.
Results: The prevalence of G20210A prothrombin mutation was similar in PAD patients and
controls (odds ratio (OR): 1.361; 95% confidence interval (CI): 0.552e3.355; pZ 0.503 after
adjustment for age, sex, smoking and presence of diabetes), but was significantly higher in
patients with Fontaine’s stage III/IV vs. those with stage II and controls (10.4% vs. 3.4% vs.
4.3%; pZ 0.02, respectively). According to a logistic multivariate model that included all
patients with PAD, the presence of the FII G20210A mutation (OR: 4.621; 95% CI: 1.548e
13.789; pZ 0.006) was associated with critical limb ischaemia after adjustment for age,
sex, smoking, presence of diabetes and the use of platelet aggregation inhibitors. The preva-
lence of the other thrombophilic alterations was not different in patients with Fontaine’s stage
III/IV, in patients with stage II and in controls.
Conclusion: These hypothesis-generating data suggest that the FII 20210A allele may be
considered as a genetic marker predisposing critical ischaemia in patients with PAD, justifying
larger longitudinal studies.
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ty for Vascular Surgery. PublisheAtherosclerotic peripheral arterial disease (PAD) is usually
a benign condition characterised by arterial stenoses and
occlusions in the peripheral arterial bed of the lower limbs.
PAD can be asymptomatic or symptomatic with differentd by Elsevier Ltd. All rights reserved.
114 M. Sartori et al.symptoms depending on the progression of the disease.
Intermittent claudication is usually the first symptom and
remains stable in 75% of patients, while a progression of the
disease leading to clinical deterioration (severe claudica-
tion or skin lesions) occurs in the remainder.1
Black race, current smoking, diabetes, hypertension,
hypercholesterolaemia and low kidney function are the
well-known risk factors for PAD.2 Diabetes and current
smoking are related to PAD progression as well.3 The role of
haemostatic factor levels and inflammatory markers, such
as D-dimer and fibrinogen, has been investigated in PAD.4
However, the true relationship between thrombophilic
abnormalities and atherosclerosis progression remains
a matter of controversy.
A recent meta-analysis showed a modest but significant
relationship between inherited thrombophilic alterations
and thrombotic arterial events.5 Thrombosis may play an
important role in the pathogenesis of atherosclerotic
complications. Genetic polymorphisms of haemostatic
factors such as G1691A factor V (FV Leiden) and G20210A
prothrombin (FII) may be involved in arterial thrombosis and
may interact with traditional cardiovascular risk factors,
leading to clinical deterioration, such as critical limb
ischaemia. Gerdes et al. showed that FII G20210A mutation
was associated with increased femoral intimal thickness and
with the occurrence of acute ischaemic events in patients
with clinically manifest atherosclerotic disease.6
In our hypotheses, the presence of FII G20210A and FV
Leiden mutations might be a limited risk factor for PAD, but
when arterial stenoses in the peripheral arterial bed are
present such mutations may be aggravating factors. Given
the large number of patients affected by PAD and the
importance of detecting the patients at risk of clinical
deterioration, the aim of the present study was to assess
the association of FII G20210A and FV Leiden mutations
with the severity of PAD symptoms.
Methods
Study population
We investigated 282 Caucasian patients (females/males:
101/181) consecutively admitted to our Angiology Unit (from
January 2005 to September 2007) for lower limb artery
disease. Subjects were diagnosed with PAD if they had clin-
ical PAD symptoms (intermittent claudication, rest pain or
gangrene), ankleebrachial index (ABI) <0.9 and significant
stenoses of leg arteries confirmed by echo-Doppler sonog-
raphy. Exclusion criteria were: PAD fromnon-atherosclerotic
causes (cardio-embolic disease, thromboangiitis obliterans,
vasculitis or congenital), presence of neoplasia and severe
dementia.
Fontaine stages were assigned as follows: class IIa, mild
claudication with a walking distance of more than 200 m;
class IIb, severe claudication with a walking distance of less
than 200 m; class III, rest pain and class IV, gangrene. Stage
III and IV were grouped as critical ischaemia.7 Stage IIa and
IIb were grouped as claudication. For analysis, patients
were divided into two groups: patients with intermittent
claudication (nZ 176) and patients with critical limb
ischaemia (nZ 106).As a control group, we selected 209 Caucasian subjects
(females/males: 87/122) referred to our outpatient
service, in whom the disease had been excluded on the
basis of physical examination and normal ABI.
The patients enrolled in the present study were
considered to have hypertension if diagnosed as hyperten-
sives according to the guidelines of the European Society of
Hypertension.8 Hyperlipidaemia was defined according to
the third report of the National Cholesterol Education
Program.9 Subjects were considered diabetic if they used
glucose-lowering medication or had fasting blood glucose
levels of 126 mg dl1 or higher. Obesity was defined as
a body mass index equal to or higher than 30 kg m2.10
The study, which complied with the Declaration of Hel-
sinki, was approved by the local Ethics Committee and
informed consent was obtained from all participants.
Vascular investigations
All PAD patients underwent bilateral ultrasonography
assessment of lower limb arteries and ABI determination.
Ultrasonography investigation was carried out with an
EnVisor C HD instrument (Philips Medical System S.p.A,
Monza, Italy), with a high-resolution broadband width
linear array transducer L 12-5 MHz, according to stand-
ardised methods.11,12 ABI was calculated according to the
American Heart Association recommendations13 and values
>0.9 were considered as normal. All investigations were
performed by a team of trained vascular physicians or
technicians. When clinically required, patients underwent
a conventional contrast angiography scanning via the
femoral or axillary route.
Blood sampling and thrombophilia screening
Blood was collected from the antecubital vein into
0.109 mmol l1 trisodium citrate. Plasma was prepared by
centrifugation for 20 min at 2000 g at room temperature
while platelet-poor plasma was snap frozen and stored at
70 C. The screening for inherited thrombophilia included
the following tests: antithrombin, protein C, protein S,
activated protein C resistance (APCR) with DNA analysis for
G1691A FV mutation in all cases with APCR normalised ratio
<0.80, and DNA analysis for FII G20210A mutation. All tests
were performed using standard methods as previously
described.14 Genotyping of G1691A FV and G20210A FII
polymorphisms was performed successfully in 100% of
subjects.
Statistical analysis
Analysis was carried out using the SPSS software package
(version 15.0; SPSS Inc., Chicago, IL, USA). Relationships
between variables were assessed using Pearson correlation
for continuous variables and chi-square or Fisher’s exact
test for categorical variables. Multivariate analysis of vari-
ance with Tukey correction for multiple comparisons was
used to compare means among groups. HardyeWeinberg
equilibrium was assessed by the chi-square test with 1 of
freedom. Odds ratios were calculated with multivariate
logistic regression analysis including the following
Peripheral Arterial Disease and Thrombophilic Mutations 115variables: G20210A FII mutation, G1691A FV mutation, sex,
age, smoking habit, the presence of diabetes and the use of
platelet aggregation inhibitors. The significance level was
set at aZ 0.05. Results are given as means SEM.
The power of the study was calculated with the ‘genetic
power calculator’ available on the web at http://statgen.
iop.kcl.ac.uk/gpc/.15 The power of the study was 0.91
(aZ 0.05) when the relative risk for PAD of 20210A carriers
was set >3.5, according to the studies of Reny et al.16 and
Sofi et al.,17 and the frequency of the A allele was set at
0.022. The power of the study increased to 0.95 if the odds
ratio (OR) for critical ischaemia in patients carrying the
20210A allele was set at 4.1, as already reported by
Reny et al.16
Results
The characteristics and traditional atherosclerosis risk
factors in patients and controls are summarised in Table 1.
Among PAD patients, 176 had intermittent claudication and
106 had critical limb ischaemia (Table 1). Sex distribution,
prevalence of hypertension, hyperlipidaemia and obesity
were similar among control subjects, patients with claudi-
cation and patients with critical limb ischaemia (Table 1).
The mean age of patients with critical ischaemia was higher
than that of control subjects (72.1 0.9 vs. 68.5 0.4
years; pZ 0.01) and of patients with claudication
(72.1 0.9 vs. 68.6 0.7 years; pZ 0.01). As expected, an
increased prevalence of smoking in patients with claudi-
cation and critical limb ischaemia was observed, whereas
the prevalence of hypertension, hyperlipidaemia and
obesity was similar among the three groups (Table 1).
Prevalence of diabetes was higher in patients with critical
ischaemia than in patients with claudication and was higher
in patients with claudication vs. control subjects (Table 1).
The distributions of genotypes of G1691A FV mutation in
the control group, in patients with claudication and in
patients with critical ischaemia were in HardyeWeinberg
equilibrium (in controls: frequency of allele G, 0.975;
frequency of allele A, 0.025; chi-squareZ 0.13; pZ 0.72; in
patients with claudication: frequency of allele G, 0.980;
frequency of allele A, 0.020; chi-squareZ 0.07; pZ 0.79; in
patients with critical ischaemia: frequency of allele G,
0.976; frequency of allele A, 0.024; chi-squareZ 0.06;
pZ 0.81). No difference was found between cases andTable 1 Characteristics of the study population.
Controls
(nZ 209)
Patients with pe
Claudication (nZ
Age (years) 68.5 0.4 68.6 0.7
Male/female 122/87 114/62
Obesity (%) 1.9 3.4
Hypertension (%) 36.4 42.0
Diabetes (%) 3.3 17.0
Hyperlipidaemia (%) 30.1 38.1
Smoking (%) 10.0 33.5
a The statistical analysis was performed by multivariate analysis of
b pZ 0.01 vs. claudication group.
c pZ 0.01 vs. control group.controls regarding the distribution of factor V G1691A
genotypes as tested by the chi-square test (Table 2) and,
accordingly, no significant OR (assessed by logistic regression
analysis) for the A allele was observed.
The distributions of genotypes of FII G20210A mutation
in the control group, in patients with claudication and in
patients with critical ischaemia were also in HardyeWein-
berg equilibrium (in controls: frequency of allele G, 0.978;
frequency of allele A, 0.022; chi-squareZ 0.1; pZ 0.75; in
patients with claudication: frequency of allele G, 0.983;
frequency of allele A, 0.017; chi-squareZ 0.05; pZ 0.82;
in patients with critical ischaemia: frequency of allele G,
0.943; frequency of allele A, 0.057; chi-squareZ 1.44;
pZ 0.23). The prevalence of FII G20210A mutation was
similar in PAD patients and controls (OR: 1.426; 95% confi-
dence interval (CI): 0.623e3.263; pZ 0.424 and OR: 1.361;
95% CI: 0.552e3.355; pZ 0.503 after adjustment for age,
sex, smoking, and presence of diabetes). As shown in
Table 2, there was a significant difference among control
subjects, patients with claudication and patients with
critical ischaemia with respect to the distribution of FII
G20210A genotypes (the presence of the A allele was
associated with critical ischaemia, with an OR vs. claudi-
cation of 3.281; CI: 1.176e9.152; pZ 0.021). According to
a logistic multivariate model, including only patients with
PAD, the presence of the FII G20210A mutation (95% CI:
1.548e13.789; pZ 0.006), diabetes, (95% CI: 1.362e4.151;
pZ 0.03) and age (95% CI: 1.009e1.071; pZ 0.01) were
associated with critical ischaemia, whereas sex distribu-
tion, smoking and the presence of FV G1691A mutation
were not (Table 3). Use of platelet aggregation inhibitors
had a negative association (Table 3).
No patient in either the PAD group or control group
had deficiencies in antithrombin, protein C or protein S
levels.
Discussion
Our study shows that the FII G20210A mutation may be
associated with more disabling stages of PAD while no
association was found between PAD and G1691A FV muta-
tion. FV Leiden and FII G20210A mutations are widely
accepted as risk factors for venous thrombo-embolism,18
but their role in arterial thrombotic disease and athero-
sclerosis is controversial.ripheral artery disease p-valuea
176) Critical ischaemia (nZ 106)
72.1 0.9b, c 0.001
67/39 0.410
2.8 0.651
34.9 0.389
35.8b, c 0.0001
27.4 0.117
33.0c 0.0001
variance for age, and the chi-square test for the other variables.
Table 2 Allele and genotype frequencies of prothrombin gene G20210A and R506Q FV Leiden mutation in Italian patients with
peripheral artery disease (PAD) and controls.
Controls
(nZ 209)
Patients with PAD p-valuea
Claudication (nZ 176) Critical ischaemia (nZ 106)
Factor V G1691A
Alleles
A 10/418 (2.5) 7/352 (2.0) 5/212 (2.4) 0.922
G 408/418 (97.5) 345/352 (98.0) 207/212 (97.6)
Genotypes
AA 0/209 0/176 0/106 0.922
GA 10/209 (4.8) 7/176 (4.0) 5/106 (4.7)
GG 199/209 (95.2) 169/176 (96.0) 101/106 (95.3)
Prothrombin G20210A
Alleles
A 9/418 (2.2) 6/352 (1.7) 12/212 (5.7) 0.01
G 409/418 (97.8) 346/352 (98.3) 200/212 (94.3)
Genotypes
AA 0/209 0/176 1/106 (0.9) 0.029
GA 9/209 (4.3) 6/176 (3.4) 10/106 (9.5)
GG 200/209 (95.7) 170/176 (93.2) 95/106 (89.6)
Data presented as number with variable/total number possible (%).
a Comparisons between the control group, claudication group, and critical limb ischaemia group were assessed by the chi-square test.
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associated with atherosclerosis progression in carotid and
femoral arteries in men.6 Reny et al.16 demonstrated that
the FII G20210A mutation was significantly associated with
the increased risk of PAD, a risk which markedly increased
with smoking. FII 20210A allele was also associated with
critical ischaemia in a multivariate analysis.16 An Italian
case-control study17 showed a significantly higher preva-
lence of FII G20210A mutation in PAD patients than in
controls, but no correlation was found with PAD stage.
Conversely, three case-control studies showed no associa-
tion between FII G20210A mutation and PAD.19e21 The
negative results of such studies can be ascribed to different
characteristics and risk profiles of the study population. In
the study of Renner et al.,19 the mean age of the controls
was 16 years younger than that of the patients. Moreover,
a low frequency of patients with more advanced stages of
PAD may have masked the effect of the FII G20210A
mutation. In a study by Mueller et al.,20 only 17% of patientsTable 3 Logistic multivariate model for critical limb
ischaemia among patients with peripheral artery disease
(nZ 282).
OR CI 95% p
Age 1.040 1.009e1.071 0.01
Sex (female vs. male) 0.911 0.524e1.581 0.70
Smoking 1.452 0.819e2.574 0.202
Presence of diabetes 1.480 1.362e4.1514 0.03
Use of aggregation inhibitors 0.379 0.222e0.649 0.001
FII 20210A allele 4.621 1.548e13.789 0.006
FV 1691A allele 0.862 0.240e3.094 0.820with PAD had critical ischaemia, a number that was even
lower in patients included in the study of Abukishe et al.21
We were able to enrol a larger number of patients with
critical ischaemia because we enrolled patients who
were older than those in the series of Reny al.16 and of
Abukishe et al.21
In the present study, we found that the prevalence of FII
G20210A mutation was not increased in patients with initial
PAD stages, suggesting a limited role of the FII G20210A
mutation in PAD aetiology. Our data suggest, albeit with the
limitations of the small sample size, that G20210A FII
mutation may become an aggravating factor, possibly
increasing the risk of critical limb ischaemia development
when PAD is already present. In fact, a prospective study has
shown that the 20210A allele is associated with atheroscle-
rosis progression in the carotid and femoral arteries in
patients with established atherosclerotic disease.6
Heterozygosity for the 20210A allele is associated with
a 25% increase in circulating prothrombin levels.22 The
association of the mutation in the prothrombin gene with
excessive thrombin generation and activation of coagulation
can lead to a ‘prothrombotic’ state.22 Arterial thrombosis
results from endovascular injury and, to a lesser extent,
alterations in haemostatic equilibrium.23 Endothelial cell
injury with the elaboration of proinflammatory mediators
stimulates the process of arterial thrombosis.23 Although this
is most often the result of atherosclerotic disease, variations
in the activity of coagulation proteins may alter the effec-
tiveness of thrombus formation, leading to PAD progression.
As seen in larger studies,3 we confirmed that age and
diabetes were associated to more severe stages of PAD. It is
well established that smoking, the ratio of total to high-
density lipoprotein (HDL) cholesterol, lipoprotein (a), high-
sensitivity C-reactive protein and diabetes are related to
PAD progression.3
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G1691A FVmutation was similar in patients with claudication
or more severe stages of PAD and in controls. It should be
noted that in a recent meta-analysis the association between
FV Leidenmutation and arterial ischaemic eventswasmodest
withanORof1.21.5Given the lownumberofpatientsenrolled
in the present study, we cannot excludewith any certainty an
association between G1691A FV and PAD. However, previous
case-control studies exploring thrombophilic risk factors in
PAD did not reveal any association.16,17,19,20
No deficiencies in antithrombin, protein C or S levels were
found in our series. Given the low prevalence of natural
inhibitor deficiencies, our study cannot exclude the possi-
bility that such risk factors may be involved in PAD progres-
sion. At present, there are no convincing data that
deficiencies of protein C, protein S or antithrombin are asso-
ciated with an increased risk of arterial thrombosis,23 but the
evaluationof theseassociations is complicatedby the relative
infrequency of such defects in the general population.
Limitations of the present study include the cross-
sectional design, the small sample size, and the possible
presence of confounders such as the higher age of patients
with critical ischaemia. Follow-up studies are necessary to
confirm the association of 20210A FII allele and PAD
progression. Nevertheless, our hypothesis-generating data
suggest that the 20210A FII allele may be considered as
a genetic marker predisposing to critical ischaemia in
patients with established PAD, and a closer follow-up may
be useful in patients with PAD carrying the FII G20210A
mutation. In our series, FII G20210A mutation was present
in 10% of PAD patients with chronic critical limb ischaemia.
In conclusion, FII G20210A mutation may be associated
withmore disabling stages of PAD, though longitudinal studies
will better clarify if this mutation is a genetic marker which
predicts an individual’s predisposition for PAD progression.
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